Towards efficient drug development modelling with machine learning.

1) Brief description of the context of the research including potential impact:
Despite significant investment, a substantial proportion of Phase III drug trials fail, contributing to delays, rising costs and unmet medical needs. One of the key challenges is accurately predicting drug effects during development, particularly in pharmacokinetics (PK) and pharmacodynamics (PD) analyses. By integrating machine learning (ML) with PK/PD modeling, this project seeks to address these challenges. Advanced data analytics, coupled with natural language processing (NLP) tools, will be used to improve drug development workflows. The potential impact includes reducing the time and cost required to bring new medications to market, improving success rates in drug trials and enhancing patient outcomes.

2) Aims and Objectives
The primary aim of this research is to develop innovative ML algorithms that can enhance drug effect predictions by integrating existing pharmacokinetic and pharmacodynamic knowledge with machine learning techniques. The specific objectives are:
- To create a comprehensive PK database that integrates open-access scientific literature and proprietary GSK data using an NLP pipeline (PKPDai).
- To develop and test ML algorithms that predict first-in-human pharmacokinetics by analyzing quantitative PK parameters and physicochemical properties.
- To expand the PKPDai pipeline to include PD data, creating a robust PK/PD database for ML applications.
- To develop automated PK/PD modeling techniques that leverage prior knowledge and improve prediction accuracy using machine learning frameworks.

3) Novelty of Research Methodology:
This research stands out for its integration of machine learning with pharmacometric modeling, leveraging prior distributions and existing PK/PD data to enhance predictive accuracy. The use of NLP pipelines to systematically extract and compile PK/PD data from literature and internal sources is another innovative element. Additionally, the...